Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173098 | 0.94 | FOLH1 (0.40) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL27571430 | 0.91 | PTGS1 (0.51) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL27571433 | 0.91 | PTGS1 (0.51) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL97583 | 0.86 | FOLH1 (0.40) | FOLH1RIMKLANAALAD2BMP1CCKBR | |
| SCHEMBL32670710 | 0.79 | PTGS1 (0.54) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL9800724 | 0.79 | FOLH1 (0.49) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL173084 | 0.79 | ALDH1A1 (0.44) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL9800723 | 0.79 | FOLH1 (0.49) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL30590010 | 0.79 | FPR1 (0.42) | — | |
| SCHEMBL26426461 | 0.79 | KEAP1 (0.40) | GLO1PTGS1GSTK1FOLH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058932-A1 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION | MAX PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20120058932-A1 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION | MAX PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058932-A1 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION | VIP, FIBP, MMP7 | GLO1 2485/4885PTGS1 1350/4885GSTK1 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.